Stock listing
KRX:185490 EyeGene, Inc. (아이진) 주가
Follow EyeGene, Inc. into a list and get an email when it puts out news.
Share price · KRX:185490
₩1,720.00 KRW +18.00 (+1.1%)
Close on Nov 20, 2026
- Day range
- ₩1,720.00 – ₩1,789.00 KRWNov 20, 2026
- Volume
- 35,817 sharesNov 20, 2026
- Market cap
- ₩74.34B KRWAt the close on Nov 20, 2026 · price × 43.22M shares outstanding
- 52-week range
- ₩1,182.00 – ₩2,805.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩206.8M KRWMedian day 63,542 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:185490 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩1,720.00 | +18.00 | +1.1% | ₩1,759.00 | ₩1,789.00 | ₩1,720.00 | 35,817 | |
| ₩1,702.00 | -7.00 | -0.4% | ₩1,726.00 | ₩1,726.00 | ₩1,620.00 | 48,834 | |
| ₩1,709.00 | -10.00 | -0.6% | ₩1,786.00 | ₩1,786.00 | ₩1,640.00 | 28,377 | |
| ₩1,719.00 | +1.00 | +0.1% | ₩1,718.00 | ₩1,797.00 | ₩1,708.00 | 25,331 | |
| ₩1,718.00 | -37.00 | -2.1% | ₩1,779.00 | ₩1,812.00 | ₩1,715.00 | 39,093 | |
| ₩1,755.00 | -14.00 | -0.8% | ₩1,780.00 | ₩1,780.00 | ₩1,712.00 | 39,753 | |
| ₩1,769.00 | +25.00 | +1.4% | ₩1,715.00 | ₩1,793.00 | ₩1,715.00 | 41,220 | |
| ₩1,744.00 | +39.00 | +2.3% | ₩1,706.00 | ₩1,799.00 | ₩1,701.00 | 49,684 | |
| ₩1,705.00 | -15.00 | -0.9% | ₩1,700.00 | ₩1,773.00 | ₩1,700.00 | 67,640 | |
| ₩1,720.00 | +28.00 | +1.7% | ₩1,699.00 | ₩1,730.00 | ₩1,610.00 | 73,998 | |
| ₩1,692.00 | 0.00 | 0.0% | ₩1,772.00 | ₩1,772.00 | ₩1,680.00 | 28,001 | |
| ₩1,692.00 | -21.00 | -1.2% | ₩1,713.00 | ₩1,788.00 | ₩1,621.00 | 83,995 | |
| ₩1,713.00 | -31.00 | -1.8% | ₩1,740.00 | ₩1,769.00 | ₩1,685.00 | 48,541 | |
| ₩1,744.00 | +39.00 | +2.3% | ₩1,651.00 | ₩1,770.00 | ₩1,651.00 | 36,580 | |
| ₩1,705.00 | -45.00 | -2.6% | ₩1,762.00 | ₩1,762.00 | ₩1,696.00 | 37,258 | |
| ₩1,750.00 | +33.00 | +1.9% | ₩1,717.00 | ₩1,797.00 | ₩1,698.00 | 41,962 | |
| ₩1,717.00 | -32.00 | -1.8% | ₩1,749.00 | ₩1,749.00 | ₩1,686.00 | 194,805 | |
| ₩1,749.00 | +69.00 | +4.1% | ₩1,680.00 | ₩1,800.00 | ₩1,675.00 | 52,408 | |
| ₩1,680.00 | -123.00 | -6.8% | ₩1,730.00 | ₩1,877.00 | ₩1,670.00 | 101,257 | |
| ₩1,803.00 | -62.00 | -3.3% | ₩1,894.00 | ₩1,895.00 | ₩1,700.00 | 56,597 | |
| ₩1,865.00 | -85.00 | -4.4% | ₩1,930.00 | ₩1,949.00 | ₩1,865.00 | 44,680 | |
| ₩1,950.00 | +14.00 | +0.7% | ₩1,935.00 | ₩1,960.00 | ₩1,905.00 | 80,823 | |
| ₩1,936.00 | -33.00 | -1.7% | ₩1,970.00 | ₩1,970.00 | ₩1,903.00 | 22,778 | |
| ₩1,969.00 | +18.00 | +0.9% | ₩1,950.00 | ₩1,980.00 | ₩1,932.00 | 39,457 | |
| ₩1,951.00 | +125.00 | +6.8% | ₩1,844.00 | ₩1,965.00 | ₩1,843.00 | 123,105 | |
| ₩1,826.00 | -65.00 | -3.4% | ₩1,830.00 | ₩1,900.00 | ₩1,801.00 | 99,041 | |
| ₩1,891.00 | +52.00 | +2.8% | ₩1,894.00 | ₩1,906.00 | ₩1,851.00 | 83,788 | |
| ₩1,839.00 | -42.00 | -2.2% | ₩1,855.00 | ₩1,881.00 | ₩1,825.00 | 86,954 | |
| ₩1,881.00 | +11.00 | +0.6% | ₩1,889.00 | ₩1,929.00 | ₩1,855.00 | 30,496 | |
| ₩1,870.00 | -9.00 | -0.5% | ₩1,879.00 | ₩1,903.00 | ₩1,854.00 | 54,245 | |
| ₩1,879.00 | +1.00 | +0.1% | ₩1,897.00 | ₩1,905.00 | ₩1,866.00 | 43,238 | |
| ₩1,878.00 | -40.00 | -2.1% | ₩1,917.00 | ₩1,927.00 | ₩1,877.00 | 70,839 | |
| ₩1,918.00 | -51.00 | -2.6% | ₩1,966.00 | ₩1,973.00 | ₩1,870.00 | 104,615 | |
| ₩1,969.00 | +34.00 | +1.8% | ₩1,988.00 | ₩1,988.00 | ₩1,921.00 | 39,046 | |
| ₩1,935.00 | +12.00 | +0.6% | ₩1,930.00 | ₩1,987.00 | ₩1,922.00 | 44,457 | |
| ₩1,923.00 | -27.00 | -1.4% | ₩1,994.00 | ₩1,994.00 | ₩1,919.00 | 42,837 | |
| ₩1,950.00 | 0.00 | 0.0% | ₩1,930.00 | ₩1,995.00 | ₩1,927.00 | 27,646 | |
| ₩1,950.00 | +20.00 | +1.0% | ₩1,930.00 | ₩1,960.00 | ₩1,925.00 | 35,327 | |
| ₩1,930.00 | -35.00 | -1.8% | ₩1,965.00 | ₩1,985.00 | ₩1,915.00 | 65,480 | |
| ₩1,965.00 | +34.00 | +1.8% | ₩1,960.00 | ₩1,985.00 | ₩1,900.00 | 79,073 | |
| ₩1,931.00 | +7.00 | +0.4% | ₩1,924.00 | ₩1,964.00 | ₩1,890.00 | 50,133 | |
| ₩1,924.00 | +18.00 | +0.9% | ₩1,906.00 | ₩1,959.00 | ₩1,902.00 | 47,971 | |
| ₩1,906.00 | -94.00 | -4.7% | ₩2,000.00 | ₩2,015.00 | ₩1,891.00 | 120,285 | |
| ₩2,000.00 | -10.00 | -0.5% | ₩2,000.00 | ₩2,050.00 | ₩1,978.00 | 86,495 | |
| ₩2,010.00 | -140.00 | -6.5% | ₩2,150.00 | ₩2,205.00 | ₩1,997.00 | 227,974 | |
| ₩2,150.00 | +85.00 | +4.1% | ₩2,020.00 | ₩2,220.00 | ₩2,020.00 | 227,502 | |
| ₩2,065.00 | -40.00 | -1.9% | ₩2,110.00 | ₩2,145.00 | ₩2,040.00 | 61,603 | |
| ₩2,105.00 | +15.00 | +0.7% | ₩2,095.00 | ₩2,135.00 | ₩2,035.00 | 108,591 | |
| ₩2,090.00 | +70.00 | +3.5% | ₩2,020.00 | ₩2,165.00 | ₩2,020.00 | 198,902 | |
| ₩2,020.00 | +30.00 | +1.5% | ₩1,990.00 | ₩2,075.00 | ₩1,974.00 | 100,647 | |
| ₩1,990.00 | +50.00 | +2.6% | ₩1,936.00 | ₩2,005.00 | ₩1,935.00 | 105,383 | |
| ₩1,940.00 | +14.00 | +0.7% | ₩1,926.00 | ₩1,959.00 | ₩1,905.00 | 106,541 | |
| ₩1,926.00 | +22.00 | +1.2% | ₩1,899.00 | ₩1,976.00 | ₩1,891.00 | 146,828 | |
| ₩1,904.00 | -4.00 | -0.2% | ₩1,910.00 | ₩1,947.00 | ₩1,885.00 | 114,747 | |
| ₩1,908.00 | -12.00 | -0.6% | ₩1,942.00 | ₩1,954.00 | ₩1,881.00 | 99,273 | |
| ₩1,920.00 | +63.00 | +3.4% | ₩1,857.00 | ₩1,939.00 | ₩1,852.00 | 113,200 | |
| ₩1,857.00 | -11.00 | -0.6% | ₩1,853.00 | ₩1,893.00 | ₩1,842.00 | 43,771 | |
| ₩1,868.00 | +22.00 | +1.2% | ₩1,934.00 | ₩1,934.00 | ₩1,845.00 | 43,971 | |
| ₩1,846.00 | -54.00 | -2.8% | ₩1,900.00 | ₩1,900.00 | ₩1,779.00 | 147,905 | |
| ₩1,900.00 | +28.00 | +1.5% | ₩1,950.00 | ₩2,150.00 | ₩1,874.00 | 434,256 | |
| ₩1,872.00 | -153.00 | -7.6% | ₩1,970.00 | ₩1,995.00 | ₩1,831.00 | 267,058 | |
| ₩2,025.00 | +210.00 | +11.6% | ₩2,305.00 | ₩2,305.00 | ₩1,955.00 | 1,456,764 |
Splits
2 splits since 2021 · KRX:185490 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 111-for-95 | Split | |
| 12-for-11 | Split |
- Ticker
- KRX:185490
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
EyeGene, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 8.0× against a median of 143×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩35.67B KRW
- P/E
- Loss
- EV/sales
- 8.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.5×
- Gross margin
- 27.8%
- Operating margin
- −276.2%
- Net margin
- −391.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| EyeGene, Inc. · KRX:185490 | US$55.57M | US$26.66M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| Tenax Therapeutics, Inc. · NASDAQ:TENX | US$56.92M | −US$56.78M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.35 |
| Kazia Therapeutics Ltd · NASDAQ:KZIA | US$56.22M | US$10.36M | n/a | 373× | n/a | 1.8× | n/a | 0.0× | 2.31 |
| OKYO Pharma Limited · NASDAQ:OKYO | US$56.15M | US$35.56M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.02 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704 | US$55.77M | US$51.65M | n/a | 9.1× | n/a | 2.5× | −43.0% | 0.3× | n/a |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Median of the others | US$55.28M | US$34.28M | 143× | 1.9× | −87.8% | 0.0× | 1.35 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 20, 2024 · Before open | +1.3% |
| Quarter to Dec 31, 2020 | Feb 24, 2021 · Before open | −3.3% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57B | 3.36B | 3.13B | 5.29B | 3.24B | 3.36B | 4.25B | 2.04B | 301.0M | 267.2M |
| Cost of revenue | 2.45B | 2.20B | 1.24B | 2.55B | 1.74B | 1.81B | 2.31B | 1.27B | 203.7M | 68.6M |
| Gross profit | 1.12B | 1.16B | 1.89B | 2.75B | 1.50B | 1.55B | 1.94B | 761.9M | 97.4M | 198.7M |
| Research and development | 5.92B | 8.27B | 20.4B | 16.3B | 28.0B | 8.82B | 5.10B | 3.78B | 5.05B | 4.69B |
| Selling, general and administrative | 1.83B | 5.57B | 7.82B | 10.0B | 8.05B | 5.55B | 5.49B | 4.80B | 3.92B | 4.00B |
| Operating income | -9.85B | -13.3B | -27.2B | -23.6B | -36.9B | -14.0B | -9.56B | -8.27B | -9.29B | -8.59B |
| Depreciation and amortization | 2.08B | 2.34B | 2.08B | 1.29B | 1.07B | 853.3M | 703.2M | 442.5M | 387.1M | 145.7M |
| EBITDA | -7.77B | -10.9B | -25.1B | -22.3B | -35.8B | -13.2B | -8.86B | -7.82B | -8.91B | -8.45B |
| Interest expense | 628.6M | 699.0M | 462.6M | 395.3M | 1.75B | 2.52B | 0 | 0 | 0 | 0 |
| Income before tax | -19.1B | -12.9B | -22.4B | -27.7B | -34.7B | -15.3B | -8.74B | -7.19B | -8.81B | -8.27B |
| Income tax | -1.17B | -84.0M | -449.9M | -1.28B | -359.4M | 1.75M | ||||
| Net income | -15.7B | -12.1B | -21.1B | -26.0B | -34.6B | -14.9B | -8.74B | -5.91B | -8.45B | -8.27B |
| Earnings per share, basic | -363.37 | -448.70 | -780.84 | -1,208.34 | -1,614.66 | -974.22 | -580.91 | -410.30 | -588.42 | -629.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.2B | 864.0M | 5.50B | 764.3M | 1.61B | 1.52B | 2.01B | 151.1M | 1.60B | 651.3M |
| Short-term investments | 35.3B | 31.1B | 49.9B | 64.4B | 83.5B | 31.5B | 35.2B | 46.6B | 20.1B | 12.1B |
| Receivables | 772.1M | 1.64B | 468.1M | 898.1M | 731.3M | 841.9M | 1.12B | 1.19B | 146.6M | 54.0M |
| Inventory | 750.7M | 585.0M | 55.2M | 498.0M | 774.4M | 704.5M | 311.1M | 206.5M | ||
| Current assets | 47.6B | 35.3B | 56.9B | 68.8B | 88.6B | 36.1B | 43.1B | 50.4B | 24.8B | 13.2B |
| Property, plant and equipment | 9.31B | 9.85B | 5.74B | 5.86B | 3.55B | 2.31B | 1.13B | 1.32B | 1.56B | |
| Total assets | 68.1B | 65.3B | 78.1B | 80.4B | 105.0B | 44.4B | 47.3B | 54.0B | 30.3B | 18.6B |
| Accounts payable | 1.30B | 1.68B | 470.7M | 863.8M | 1.89B | 1.53B | 931.9M | 591.0M | ||
| Current liabilities | 10.0B | 11.0B | 6.10B | 4.92B | 9.61B | 8.49B | 17.5B | 1.59B | 1.25B | 1.16B |
| Long-term debt | 1.06B | 0 | 0 | 11.5B | 2.52B | 22.2B | 3.79B | |||
| Total debt | 11.7B | 2.87B | 22.2B | 3.79B | ||||||
| Total liabilities | 13.8B | 15.0B | 13.8B | 13.7B | 16.0B | 31.5B | 28.3B | 30.7B | 6.53B | 2.37B |
| Shareholders' equity | 57.1B | 50.3B | 63.2B | 66.7B | 89.0B | 12.9B | 19.0B | 23.3B | 23.8B | 16.2B |
| Shares outstanding | 43.2M | 27.0M | 27.0M | 21.5M | 21.4M | 15.3M | 15.0M | 14.4M | 14.4M | 13.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.98B | -12.2B | -20.1B | -18.6B | -30.0B | -9.75B | -8.32B | -7.48B | -6.76B | -5.99B |
| Capital spending | -1.22B | -4.99B | -1.67B | -767.9M | -2.38B | -2.03B | -990.9M | -243.4M | -272.7M | -1.49B |
| Free cash flow | -7.20B | -17.2B | -21.8B | -19.5B | -32.8B | -11.8B | -9.31B | -7.73B | -7.03B | -7.48B |
| Cash from investing | 7.34B | 5.67B | 17.2B | -56.7B | 4.45B | 11.1B | -27.0B | -8.28B | 616.0M | |
| Cash from financing | 646.5M | 17.9B | 880.0M | 86.6B | 4.14B | 403.1M | 30.7B | 18.7B | 288.3M | |
| Share buybacks | 15.0B | 3.41B | 88.2B | 228.6M | 662.0M | 467.0M | 13.1B | 172.5M | ||
| Change in cash | 8.77B | -4.07B | 3.45B | -603.2M | -74.0M | -1.11B | 3.15B | -3.72B | 3.62B | -5.08B |
Cap table
Built by 6ix from EyeGene, Inc.’s releases
- Common shares
- 43,222,876
- Fully diluted
- 43,222,876
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 43,222,876 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 43,222,876 |
Log in to ask 6ix AI your own questions about EyeGene, Inc.